Plus Therapeutics' subsidiary CNSide Diagnostics secured a new coverage agreement with Blue Shield of California for its CNSide® Cerebrospinal Fluid Tumor Cell Enumeration assay, effective April 2026. This expands CNSide's covered lives from 75 million to 81 million, enhancing access for patients with metastatic central nervous system cancers. The assay enables earlier and more accurate detection of leptomeningeal metastases, improving treatment decisions and reducing healthcare costs by about 40%. This move supports Plus Therapeutics' goal to reach 150 million covered lives in 2026 and accelerates adoption across oncology centers by easing reimbursement barriers.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
Garmin introduced the G2000 PRIME, a new integrated flight deck designed for high-performance Class I/II piston and electric aircraft. It features large, edge-to-edge touchscreen displays with advanced multi-touch capabilities, faster processors, and...
UniFirst Corporation has been recognized on Selling Power's 60 Best Companies to Sell For list for the 23rd consecutive year, highlighting its strong sales culture and support for sales professionals. The list evaluates companies on compensation, tra...
